The last is EMERALD (NCT03778931), an international multicentre phase III study, which will compare the efficacy and safety of elacestrant to physician’s choice endocrine monotherapy (an AI or fulvestrant) in patients with ESR1-mutated ER+/HER2-negative metastatic BC. This evidence concerns the gene ESR1 and breast cancer.